744183-20-8

Basic information

• Product Name: N-Boc-exo-3-aminotropane
• Synonyms: (3-exo)-3-Amino-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester;N-Boc-exo-3-aminotropane;exo-3-Amino-8-Boc-8-azabicyclo[3.2.1]octane;exo-3-Amino-8-Boc-8-azabi...;tert-Butyl exo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate;(1R,3r,5S)-rel-tert-Butyl 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate;exo-3-Amino-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester;tert-butyl (1R,3s,5S)-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate
• CAS NO: 744183-20-8
• Molecular Formula: C₁₂H₂₂N₂O₂
• Molecular Weight: 226.32
• Mol File: 744183-20-8.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 313.215 °C at 760 mmHg
• Flash Point: 143.227 °C
• Appearance: /
• Density: 1.084
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.12±0.20(Predicted)
• CAS DataBase Reference: N-Boc-exo-3-aminotropane(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-exo-3-aminotropane(744183-20-8)
• EPA Substance Registry System: N-Boc-exo-3-aminotropane(744183-20-8)

Safety Data

• Hazardous Substances Data: 744183-20-8(Hazardous Substances Data)

Usage

General Description

N-Boc-exo-3-aminotropane, also known as 3-(2-aminophenyl) cyclohexanol, is a chemical compound with a molecular formula of C13H19NO2. It is a derivative of cyclohexanol and contains a Boc (tert-butoxycarbonyl) protective group attached to the exo-amine group. N-Boc-exo-3-aminotropane is often used in organic synthesis as a building block for creating other compounds or pharmaceuticals. It is also used as a precursor in the production of various drugs and bioactive compounds. Its specific structure and reactivity make it valuable in the pharmaceutical industry for the preparation of complex molecules.

Upstream product

• 185099-67-6 Boc-tropinone 
• 538-09-0 nortropine 
• 1307867-04-4 tert-butyl (exo)-3-azido-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 939960-39-1 (1R,3S,5S)-tert-butyl 3-((methylsulfonyl)oxy)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 143557-91-9 (1R,3S,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 185099-67-6 N-Boc-nortropinone 
• 1006867-18-0 (1S,3S,5R)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 
• 944123-76-6 1,1-Dimethylethyl 3-[(phenylmethyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 207564-70-3 tert-butyl (1R,3r,5S)-3-(benzylamino)-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 28957-72-4 N-benzylnortropinone 
• 24424-99-5 di-tert-butyl dicarbonate 
• 542-05-2 acetonedicarboxylic acid 

Downstream Products

• 1006867-19-1 C₂₀H₂₅F₄N₃O₃ 

Relevant articles and documents

HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS

This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes

We described the discovery and optimization of a novel series of pyrimidopyrimidine derivatives as G-protein coupled receptor 119 (GPR119) agonists against type 2 diabetes. Most designed compounds displayed significant GPR119 agonistic activities. Optimized analogues 15a and 21e exhibited highly potent agonistic activities with single digit EC50 values (2.2 nM and 8.1 nM, respectively). Therefore, 15a and 21e were evaluated for their oral glucose tolerance test (oGTT) in C57BL/6N mice. Compound 15a reduced the blood glucose area of under curve from 0 to 2 h (AUC0–2h) to 13.5% at the dose of 15 mg/kg comparing with Metformin reduced 18% of AUC0–2h at the dose of 300 mg/kg.

An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: The discovery of N -{(1 S)-1-(3-fluorophenyl)-3-[(3- endo)-3-(5-isobutyryl-2- methyl-4,5,6,7-tetrahydro-1 H -imidazo[4,5- c ]pyridin-1-yl)-8-azabicyclo[3.2.1] oct-8-yl]propyl}acetamide (PF-232798)

Preventing entry of HIV into human host cells has emerged as an attractive approach to controlling viral replication. Maraviroc 1 is an approved antagonist of the human CCR5 receptor which prevents the entry of HIV. Herein, we report the design and discovery of a series of imidazopiperidine CCR5 antagonists which retain the attractive antiviral profile and window over hERG activity of maraviroc 1, combined with improved absorption profiles in rat and dog. Furthermore, this series of compounds has been shown to retain activity against a laboratory generated maraviroc-resistant HIV-1 strain, which indicates an alternative resistance profile to that of maraviroc 1. Compound 41f (PF-232798) was selected as a clinical candidate from the imidazopiperidine series and is currently in phase II clinical trials.